Healthcare shares are flat in pre-market trade.
Regeneron Pharmaceuticals ( REGN ) is up 0.91% at $284.25 in the pre-market session after it reported Q3 EPS of $2.40, beating the Capital IQ consensus estimate of $1.86. Revenues of $597 million also topped the consensus of $503.74 million.
And, Zoetis ( ZTS ) reported Q3 EPS of $0.34, ex one-time items, in line with the Capital IQ consensus estimate. Revenues of $1.1 billion were just above the consensus of $1.06 billion.
The company now projects FY13 EPS of $1.38 - $1.42, from the prior guidance of $1.36 - $1.42; the consensus is for EPS of $1.40. Revenues are now seen to be $4.475 billion - $4.525 billion, from the previous outlook of $4.425 billion - $4.525 billion; analysts are looking for $4.49 billion.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.